Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ethanolamine oleate + iopamidol
- Development stage
- Unknown
- Lead developer
- Chiba University Hospital Startup Support Fund
- Modality
- Small Molecules
- Administration
- Percutaneous
01
Overview
Ethanolamine oleate + iopamidol (EOI) is a combination vascular sclerosant and embolic agent used in interventional radiology, specifically for balloon-occluded retrograde transvenous obliteration (BRTO). It consists of 5% ethanolamine oleate, a fatty acid derivative that acts as a sclerosing agent by causing endothelial damage and subsequent thrombosis, mixed with iopamidol, an iodinated contrast medium that allows for fluoroscopic visualization during the procedure. An investigational foam formulation, created by mixing EOI with carbon dioxide, is being evaluated for its potential to improve efficacy and safety in treating portal hypertension and portosystemic shunts, such as gastric varices and splenorenal shunts. The development is primarily associated with Chiba University Hospital.
- Other names
- ethanolamine oleate with iopamidolEOI foam
Beyond the preview
Go deeper on ethanolamine oleate + iopamidol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ethanolamine oleate + iopamidol.